VaxGen Anthrax Vaccine Delayed
This article was originally published in The Pink Sheet Daily
Executive Summary
VaxGen expects to supply its recombinant protective antigen anthrax vaccine to the U.S. government beginning in the fourth quarter of 2006, the firm announced Nov. 1
You may also be interested in...
Clinical Hold For VaxGen's Anthrax Vaccine Could Lead To Termination Of HHS Contract
FDA puts Phase II trial for investigational anthrax vaccine on hold due to stability concerns.
Clinical Hold For VaxGen's Anthrax Vaccine Could Lead To Termination Of HHS Contract
FDA puts Phase II trial for investigational anthrax vaccine on hold due to stability concerns.
VaxGen Warning Letter Questions Anthrax Vaccine Promotions
CBER’s advertising branch cites VaxGen for promotions of its experimental anthrax vaccine, but the claims resemble those made in a 2004 HHS press release.